Brief: Sensei Biotherapeutics Signs Research And Development Agreement With National Cancer Institute
06/02/2023 15:38
Feb 6 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS SIGNS COOPERATIVE RESEARCH AND
DEVELOPMENT AGREEMENT (CRADA) WITH THE NATIONAL CANCER INSTITUTE
(NCI) TO EXPAND DEVELOPMENT PLAN FOR SNS-101, A CONDITIONALLY
ACTIVE VISTA-BLOCKING ANTIBODY
* SENSEI BIOTHERAPEUTICS INC - EXPECTS TO SUBMIT AN
INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR SNS-101 IN OR
BEFORE APRIL 2023
* SENSEI BIOTHERAPEUTICS INC - SNS-101 TRIAL IS EXPECTED TO
COMMENCE THEREAFTER IN 2023, PENDING REGULATORY CLEARANCE
Source text for Eikon: ID:nGNX3XqjN9
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)